Enoblituzumab + Retifanlimab + Tebotelimab
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
Trial Timeline
Mar 17, 2021 → Jul 29, 2022
NCT ID
NCT04634825About Enoblituzumab + Retifanlimab + Tebotelimab
Enoblituzumab + Retifanlimab + Tebotelimab is a phase 2 stage product being developed by MacroGenics for Head and Neck Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04634825. Target conditions include Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04634825 | Phase 2 | Terminated |
Competing Products
20 competing products in Head and Neck Cancer